Articles - HSPC A specially curated list of peer-reviewed articles discussing the latest advancements in the diagnosis and treatment of patients with HSPC. AllAbiraterone AcetateAndrogen-Deprivation TherapyAndrogen-Receptor InhibitorApalutamideCancerClinical TrialsConferenceDarolutamideDocetaxelDoublet TherapyEnzalutamidemCSPCmHSPCPrednisolonePrednisoneProstate-Specific AntigenRadiotherapyTriplet Therapy Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial READ MORE Treatment options for metastatic hormone-sensitive prostate cancer READ MORE The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups READ MORE Cancer treatment and survivorship statistics, 2022 READ MORE Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy READ MORE Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice READ MORE Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins READ MORE Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer READ MORE Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design READ MORE Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis READ MORE Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer READ MORE Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer READ MORE Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk READ MORE Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol READ MORE Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings READ MORE Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer READ MORE Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis READ MORE Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study READ MORE Prostate-specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer READ MORE Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer READ MORE Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer–specific mortality READ MORE Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer READ MORE Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial READ MORE Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial READ MORE Facebook Twitter Linkedin
